Background: Guidelines for the 2-min tidal-breathing and the five-breath dosimeter methods for methacholine challenge have recently been published by the American Thoracic Society (ATS). Although subjects are exposed to twice as much aerosol at any given concentration during the tidal-breathing method compared to the dosimeter method, they were thought to give equivalent results. 
M
ethacholine challenge is a widely performed test for both diagnostic and research purposes. Recently, the American Thoracic Society (ATS) published guidelines 1 for two of the more commonly used methods: the 2-min tidal breathing method, 2 and the five-breath dosimeter method. 3 At any given concentration, subjects are exposed to approximately twice as much aerosol with the tidal-breathing method as compared to the dosimeter method. However, equivalent results have been demonstrated in two small studies, an older study 4 using histamine, and a more recent study 5 in which the dosing regimens for the two methods were not identical. We compared the two methods described in the ATS guidelines in a larger cohort of subjects using identical regimens.
Materials and Methods

Subjects
Subjects with asthma 6 were recruited from the respiratory clinic at the Royal University Hospital and from advertisements. Inclusion criteria included an FEV 1 Ն 65% predicted and a tidal-breathing provocative concentration of methacholine caus-ing a 20% fall in FEV 1 (PC 20 ) Ͻ 16 mg/mL. The study was approved by the University of Saskatchewan Ethics Committee, and signed informed consent was obtained.
Study Design
Subjects (n ϭ 40) attended the laboratory on 2 days at the same time of day within 1 week. Inhaled albuterol (n ϭ 39) or terbutaline (n ϭ 1) was withheld for 6 h, and long-acting ␤ 2 -agonists (n ϭ 3) for 36 h and inhaled corticosteroids (n ϭ 9) were continued in the same dosage; no other asthma medications were used. Subjects had no relevant allergen exposure, respiratory tract infection, or change in asthma maintenance therapy for at least 4 weeks. Two methacholine challenges, one using each method, were performed in random order.
Tidal-Breathing Method
The 2-min tidal-breathing method was performed as outlined 1,2,7 ; Bennett Twin jet nebulizers (Puritan-Bennett Corporation; Carlsbad, CA) were calibrated with 3 mL of saline solution by weighing before and after a 2-min period of nebulization to deliver a mass loss of 0.13 g/min approximating an output of 0.13 mL/min. Aerosols were directed to the subject via a loose-fitting facemask. Subjects wore a nose clip and inhaled each aerosol for 2 min of tidal breathing. Sterile isotonic saline solution was initially inhaled followed by doubling concentrations starting as outlined in previous publications. 7, 8 The available concentrations ran from 0.03 to 16 mg/mL. Full spirograms were initially done in triplicate. After the completion of each inhalation, single technically acceptable truncated spirograms were performed to obtain an FEV 1 at both 30 s and 90 s. The dose step-up timing was kept constant with a 5-min time interval between the commencement of one concentration and the commencement of the next. The percentage fall in FEV 1 was calculated from the lowest post-saline solution FEV 1 to the lowest post-methacholine FEV 1 . 2, 7, 9 The test was continued until the FEV 1 had fallen by 20%, and the PC 20 was calculated. 10 
Dosimeter Method
The dosimeter method 1, 3 was performed using DeVilbiss 646 nebulizers (Sunrise Medical HHG; Somerset, PA) and a KoKo dosimeter (Pulmonary Data Services; Doylestown, PA). The DeVilbiss 646 nebulizers were calibrated to produce a mass loss of 9 mg per actuation, approximately equivalent to 9 L per breath. Triplicate calibrations were done with 3 mL in the nebulizer by having the calibrator take 10 slow-breath activations from functional residual capacity to total lung capacity (TLC) followed by a 5-s breathhold and exhalation to the room. The five-breath dosimeter methacholine challenge was done using the identical methacholine solutions (0.03 to 16 mg/mL), starting concentration, FEV 1 timing, dose step-up timing, PC 20 calculation, etc., as the tidal-breathing method. Only the inhalation method was different. The method of inhalation was five slow inspiratory capacity (functional residual capacity to TLC) inhalations followed by a 5-s breathhold at TLC with exhalation to the room following each inhalation.
Analysis
The primary end point, the PC 20 , was log transformed and analyzed by paired t test using a computerized statistical program. 11 
Results
Forty subjects meeting the inclusion criteria of an FEV 1 Ն 65% and a tidal-breathing PC 20 Ͻ 16 mg/mL completed the investigation without adverse events. A forty-first subject failed to return for the second methacholine challenge and was not included in the analysis. Demographics of the 40 subjects who completed both challenges are given in Table 1 .
Individual data points for the two methacholine challenges are compared in Figure 1 . Three subjects with tidal-breathing PC 20 values ranging from 1.9 to 4.3 mg/mL had a Ͻ 10% FEV 1 fall at 16 mg/mL with the dosimeter method; this was extrapolated to a PC 20 Ͼ 32 mg/mL, a conservative estimate that was used for the statistical analysis (ie, PC 20 ϭ 32). The dosimeter PC 20 was almost twofold greater than the tidal-breathing PC 20 , with geometric mean values of 2.4 mg/mL (95% confidence interval, 1.5 to 3.7 mg/mL) and 1.3 mg/mL (95% confidence interval, 0.93 to 1.9 mg/mL), respectively (p Ͻ 0.00005). When the three subjects with extrapolated high PC 20 values were omitted from the analysis, the geometric mean dosimeter PC 20 remained 1.6-fold larger than the tidal-breathing PC 20 (p Ͻ 0.00005).
We made the post hoc observation that subjects with higher PC 20 values appeared to have a greater difference between the two methods. Accordingly, the population was arbitrarily dichotomized into the 25 subjects with a tidal-breathing PC 20 Ͼ 1 mg/mL (mild-to-borderline AHR) and 15 subjects with a tidal-breathing PC 20 Ͻ 1 mg/mL (moderate-tomarked AHR). We compared the ratio of the dosimeter PC 20 to the tidal-breathing PC 20 and found a ratio of 3.2 for those with PC 20 values Ͼ 1 mg/mL, and 1.6 mg/mL for those with PC 20 Ͻ 1 mg/mL (unpaired t test, p ϭ 0.04). When this analysis was repeated omitting the three subjects with extrapolated PC 20 values, the ratios were 2.1 and 1.6, respectively (p ϭ 0.19).
Two of the three subjects with PC 20 values extrapolated to Ͼ 32 mg/mL returned to the laboratory for repeat dosimeter PC 20 determinations using sub-TLC inhalations and breathhold. These two subjects both had measurable dosimeter PC 20 values with the sub-TLC inhalation method (12.0 mg/mL and 4.2 mg/mL).
Discussion
We have compared the two standardized methacholine challenges with the only differences in protocol being the method of aerosol generation and the method of inhalation. In the entire group, the geometric mean dosimeter PC 20 was almost twice that of the tidal-breathing PC 20 . The discrepancy was greater (2.1-fold) in those with tidal-breathing PC 20 Ͼ 1.0 mg/mL and less (1.6-fold) in those with tidal-breathing PC 20 Ͻ 1 mg/mL. Adding to this discrepancy were an additional three subjects with tidal-breathing PC 20 values approximately 2.0 to 4.0 mg/mL and dosimeter PC 20 values unmeasurable at Ͼ 32 mg/mL. There are many potential reasons for these observations and some possibilities are outlined below.
The dose of aerosol delivered to subjects would be the most obvious and likely most important difference between the two methods. The tidal-breathing method produces an aerosol of 0.13 mL/min for 2 min, giving a total output of 0.26 mL or 260 L.
When this is multiplied by the duty cycle (total duration of respiratory cycle/total breathing cycle time, approximately 0.35), the subject will be exposed to approximately 90 L at each concentration. This compares to 45 L (five breaths ϫ 9 L per breath) at each concentration for the dosimeter method. The approximate double dose administered by the tidal-breathing method would account for the PC 20 being approximately one half that of the dosimeter method.
The deposition and retention of aerosol are likely different between methods. It was empirically assumed 1 that the slow inspiratory capacity breath and breathhold might result in a superior dose and aerosol retention, which might explain the apparent PC 20 equivalence in the earlier histamine provocative concentration comparison between two methods. 4 In that study, 4 the two methods produced equivalent lung deposition of radiolabeled aerosol; however, the method of dosimeter calibration (see below) was not specified. The mean data suggest that greater aerosol retention is not a factor in our study. However, subjects with moderate-to-marked AHR showed less than the expected 2:1 ratio in provocative concentration values, suggesting greater dosimeter aerosol dose/deposition may have played a role in this group of subjects. A third consideration in the differences of the method is the effect of maximal inspiration on the measurement of airway responsiveness. Inhalations to TLC are recognized to be bronchodilator and bronchoprotector, particularly in subjects with airway responsiveness in the normal, borderline, or mild range. 12 This is important enough so that delaying the time to the first spirogram (ie, until the first inhalation to TLC) following methacholine inhalation to 3 min as opposed to 30 s results in a significantly lower PC 20 values across all ranges of airway responsiveness. 13 We kept the timing and the number of spirograms constant so this was not a factor in any difference between the two methods. However, the dosimeter method involves five inhalations to TLC with 5-s breathholds. Consequently, the subjects spend a total of 25 to 30 s breathholding at TLC in the 1.0 to 1.5 min before the first spirogram. The bronchodilator/bronchoprotective effect of this maneuver is the likely explanation for the greater discrepancy between the two methods seen in subjects with mild AHR. It also would explain the three subjects with mild-to-borderline AHR on the tidal-breathing method whose PC 20 values were unmeasurable with the dosimeter method. Indeed, this was verified in two of these subjects by repeating the dosimeter PC 20 with sub-TLC inhalations and obtaining measurable PC 20 values. Further investigation into this observation is warranted.
A fourth concern regarding comparative studies looking at the two methods is the mechanism of dosimeter nebulizer calibration. We have demonstrated large variations in apparent measured nebulizer output with dosimeter-nebulizer systems based on how the calibration is performed. As noted above, we routinely calibrate our dosimeter nebulizer systems by weighing the nebulizer before and after breath activation followed by exhalation into the room. When the nebulizers are operated at these running parameters and the nebulizer recalibrated by having the subject breath activate the nebulizer and exhale back into the nebulizer, the measured output (mass loss) is less by about a factor of one third, likely because of condensation from the exhaled breath within the nebulizer. The result is an underestimate of the mass loss. 14 When the nebulizer is activated by manual activation (activation via a switch with no subject inhaling), the measured output, when operated at these parameters, is less by a factor of two thirds, almost certainly because the aerosol does not completely clear the dead space of the nebulizer and remains within. Conversely, if the nebulizer dosimeter operating parameters are adjusted to obtain a measured output of 9 L per breath using the latter two methods, the operating characteristics have to be increased such that the true output is greater. It is possible that differences in nebulizer calibration in different studies could explain in whole or in part different comparative results.
The two previous methods comparison investigations have suggested similar PC 20 values by the two tests. Ryan et al 4 examined histamine PC 20 using 2-min tidal breathing method with a Wright nebulizer at a slightly higher output than usual (0.147 mL/min) and a very small particle size: aerodynamic mass median diameter of (AMMD) 0.87 m. This was compared to a dosimeter method using a nebulizer (model 646; DeVilbiss; Minneapolis, MN) calibrated (means unspecified) to an output of 9 L per breath and operated by a Rosenthal-French dosimeter. There were 10 subjects in this study. Geometric mean PC 20 was 1.8 mg/mL with tidal breathing and 2.2 mg/mL with the dosimeter method. This study may not be comparable to ours for at least two reasons. The first is the method of dosimeter calibration was not specified, and this could have influenced the study. The second is that the very small Wright nebulizer particle size may be the reason for reduced effect produced by some (particularly Canadian-made) Wright nebulizers 15 ; the small particle size aerosol may behave in part like a gas with a greater proportion of aerosol being exhaled. The reduced response produced by the Canadian Wright nebulizer is the major reason that we switched to the Bennett Twin jet nebulizer, which has a more appropriate particle size with the AMMD between 3 m and 4 m. 16 The other methods comparison study 5 compared the tidal-breathing method using doubling-dose steps of methacholine and a Canadian Wright nebulizer, and the dosimeter method using quadrupling-dose steps (a recommended ATS option) and the DeVilbiss 646 nebulizer. Eleven of the 12 subjects were evaluable with a geometric mean PC 20 of 4.7 mg/mL for tidal breathing and 3.9 mg/mL for dosimeter. The different dosages make comparison difficult; however, since there is a significant cumulative effect of methacholine when administered at 5-min intervals, 13 the cumulative effect should be smaller with quadrupling doses. If so, this should contribute to the dosimeter PC 20 being higher (rather than lower) than with doubling doses; therefore, this is not a plausible explanation for why their study differs from ours. Their tidal-breathing method used a Canadian Wright nebulizer, some of which have been previously demonstrated to produce a markedly lower response than the English Wright nebulizer 15 probably because of the very small particle size (AMMD Ͻ 1 m). Thus, some Canadian Wright nebulizers may underestimate AHR. The particle size of the nebulizer used in the study by Wubbel et al 5 is not specified. Likewise, the means of calibration of the dosimeter nebulizer system discussed above (DeVilbiss) was also not specified. Several other studies [17] [18] [19] [20] cannot be compared to ours because of methodologic differences or lack of documentation of nebulizer output.
These results indicate that when the tests are done as outlined by the ATS, different cut points should be used for the different methods. The ATS has suggested 16 mg/mL as the cut point between normal and borderline, 4 mg/mL as the cut point between borderline and mild, and 1 mg/mL as the cut point between mild and moderate to marked. 1 These are based on the tidal-breathing method. 7 Based on the current study, the cut points should be increased to 32 mg/mL, 8 mg/mL, and 2 mg/mL, respectively, for the dosimeter method.
Both methods were well tolerated. Subjects indicated a slight preference (not significant) in favor of the tidal-breathing method, which was perceived as easier; several subjects expressed no preference. From a scientific point of view, it has been believed that there was generally very little to choose between the two methods when properly standardized. 1, 3, 4, 7 However, our observation of several subjects with clinical asthma, mild AHR by the tidal-breathing method, and no measurable airway hyperresponsiveness by the dosimeter method would suggest that the bronchodilator/bronchoprotective effect of the dosimeter method itself may, in fact, reduce the sensitivity of the test and lead to some false-negative test results in subjects at the mild end of the AHR spectrum. This is the area where the majority of positive test results are likely to occur in clinical practice when testing subjects with symptoms and normal spirometry.
